Last reviewed · How we verify
NCT05373095: RKPK: Phase II
Rudi Kundini, Pamoja Kundini
NA trial testing PKC (adapted adherence counseling) and Conditional Cash Transfers in HIV (Human Immunodeficiency Virus) in 692 participants. Participants enrolled and being followed up; not accepting new ones.
20 January 2026
Quick facts
| Lead sponsor | University of California, Berkeley |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 692 |
| Start date | 23 October 2023 |
| Primary completion | 20 January 2026 |
| Estimated completion | 20 January 2026 |
| Sites | 4 locations across Tanzania |
Drugs / interventions tested
- PKC (adapted adherence counseling) and Conditional Cash Transfers
Conditions studied
- HIV (Human Immunodeficiency Virus) — all drugs for HIV (Human Immunodeficiency Virus) →
Sponsor
University of California, Berkeley
Who can join
18 and older, any sex, with HIV (Human Immunodeficiency Virus). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This protocol describes an individually randomized trial that will include adult people living with HIV (PLHIV) currently receiving HIV care at one of two participating health facilities and identified as high risk for disengagement from care by a machine learning algorithm. Participants randomized to the control arm will receive standard of care HIV clinical services according to Tanzania's National Guidelines for the management of HIV. For those who meet clinic eligibility criteria for enhanced adherence counseling, which at the included study sites is when client's viral load reaches a detectable level (\>1000 copies/ml), this includes the standard provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions, starting on the day of the result and for two months after. Intervention arm participants will receive the same standard HIV care services plus the offer of a cash transfer paired with visit attendance and attendance at each of the three adapted enhanced adherence counseling sessions (referred to as PKC sessions).
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Impact of financial incentives on viral suppression among adults initiating HIV treatment in Tanzania: a hybrid effectiveness-implementation trial.
Njau PF, Katabaro E, Winters S, Sabasaba A, et al · · 2024 · cited 5× · PMID 39098325 · DOI 10.1016/s2352-3018(24)00149-8 -
Prevention of adverse HIV treatment outcomes: machine learning to enable proactive support of people at risk of HIV care disengagement in Tanzania.
Xie Z, Hu H, Kadota JL, Packel LJ, et al · · 2024 · cited 2× · PMID 39317499 · DOI 10.1136/bmjopen-2024-088782 -
Rudi Kundini, Pamoja Kundini (RKPK): study protocol for a hybrid type 1 randomized effectiveness-implementation trial using data science and economic incentive strategies to strengthen the continuity of care among people living with HIV in Tanzania.
Kadota JL, Packel LJ, Mlowe M, Ulenga N, et al · · 2024 · cited 1× · PMID 38336793 · DOI 10.1186/s13063-024-07960-x -
Rudi Kundini, Pamoja Kundini (RKPK): study protocol for a hybrid type 1 randomized effectiveness-implementation trial using data science and economic incentive strategies to strengthen the continuity of care among people living with HIV in Tanzania
Kadota JL, Packel LJ, Mlowe M, Ulenga N, et al · · 2023 · DOI 10.21203/rs.3.rs-3315136/v1
Verify or expand the search:
- PubMed search for NCT05373095
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV (Human Immunodeficiency Virus)
Currently open trials in the same condition.
- NCT07495059 — Adaptation and Implementation of an Evidence-based Approach to Advance HIV Prevention and Care · NA · recruiting
- NCT07115901 — Guaranteed Income to Boost HIV Care Continuity and Suppression Post-Jail Release · NA · recruiting
- NCT07336797 — Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy · Phase 2 · recruiting
- NCT07062614 — Exploration of the Variability of Exposure to Antiretroviral Treatment in Hair With a View to Validating Its Value as a · recruiting
- NCT07150871 — Impact of Covid-19 on Syphilis · active not recruiting
Other University of California, Berkeley trials
Trials by the same sponsor.
- NCT07281313 — Aphasia Physical EXercise Study: Randomized Trial · NA · recruiting
- NCT07186816 — SUpport From PEeRs to Expand Access Study - Community · NA · recruiting
- NCT06956430 — Mitigating Heat Stress Among Rickshaw Drivers in Bangladesh · NA · not yet recruiting
- NCT06979258 — Heat Stress Exposure Among Low-Income Residents in Bangladesh and Evaluation of Indoor Interventions · NA · recruiting
- NCT06947187 — Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05373095 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Berkeley
- Last refreshed: 30 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05373095.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing